Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Intel CEO Brian Krzanich. Photo by Horacio Villalobos /Getty Images

Intel CEO Brian Krzanich sold more than $39 million worth of company stock after Intel learned of a fundamental design flaw in its products, but before the general public was made aware.

Why it matters: The SEC may take a hard look at Krzanich's windfall, particularly the part where he changed the rules governing his stock sale schedule.

The timeline

June 4, 2015: Krzanich adopts a new Rule 10b5-1 trading plan. Such plans are regularly used by company executives to establish automated stock sale calendars, so as to eliminate accusations of insider trading.

April 22, 2016: Krzanich adopts a new Rule 10b5-1 trading plan.

February 10, 2017: Krzanich adopts a new Rule 10b5-1 trading plan.

June 2017: Google security researchers inform Intel and other large chipmakers of security vulnerabilities related to longstanding processor designs. Per Intel:

"The security researchers presented their findings in confidence, and we and other companies worked together to verify their results, develop and validate firmware and operating system updates for impacted technologies, and make them widely available as rapidly as possible."

October 30, 2017: Krzanich again changes the terms of his Rule 10b5-1 trading plan. The prior two changes had come after 10-month periods. This one came after an 8-month period.

November 29, 2017: Krzanich sells more than $39 million worth of Intel stock, in accordance with the revised trading plan adopted just weeks earlier. It represents the sale of all but 250,000 shares, which is the minimum amount that Intel requires Krzanich to hold.

January 3, 2018: Intel and other chipmakers publicly disclose the security flaw.

The explanation

An Intel spokeswoman says that Krzanich's October 2017 trading plan change and subsequent stock sale were "unrelated" to the chip design flaw, but declined to provide any alternate explanation.

Intel also says that it does not expect material financial impacts from the design flaw, although it remains too early to know for sure.

While Intel shares took a hit from yesterday's revelation, they continue to trade higher than where Krzanich sold last November. Such fluctuations, however, would be irrelevant to an insider trading investigation.

Bottom line: Executives are typically allowed to sell shares via automated trading programs even if they know of non-public material information, but that's much different from changing the terms of the program once in receipt of such knowledge. For Krzanich, the key could be whether regulators agree with Intel's contention that the design flaw is non-material.

Go deeper

Biden Day 1 challenges: Cities getting desperate

Illustration: Aïda Amer/Axios

Dire budget problems in cities from coast to coast mean that furloughs and layoffs of essential workers could ring in the new year. So President-elect Joe Biden will face instant, high-stakes calls for relief. 

Why it matters: Suffering municipalities say there's no way they can tackle COVID-19 and all their other problems without direct and immediate aid.

The pandemic is as bad as it's ever been

Expand chart
Data: The COVID Tracking Project, state health departments; Map: Andrew Witherspoon, Sara Wise/Axios

No state in America could clear the threshold right now to safely allow indoor gatherings.

The big picture: This is bad as the pandemic has ever been — the most cases, the most explosive growth and the greatest strain on hospitals. If businesses were closed right now, it would not be safe to reopen them. And holiday travel will be risky no matter where you’re coming from or where you’re going.

Oxford University coronavirus vaccine trials show strong immune response

CSL chief scientific officer Andrew Nash with a small vial to go into the bioreactor to create 30 ml doses of the AstraZeneca vaccine on Nov. 8 in Melbourne, Australia. Photo: Darrian Traynor/Getty Images

A COVID-19 vaccine from Oxford University and AstraZeneca is safe and produces strong immune responses in older, preliminary findings of a phase two trial published in the Lancet Thursday show.

Why it matters: Coronavirus cases are soaring in the U.S. and across the world. The findings from the study of 560 healthy adults, including 240 people aged over 70, follow Pfizer's announcement Wednesday that its vaccine is 95% effective and Moderna's data released Monday showing its version has a 94.5% vaccination success rate.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!